Reporting rates of yellow fever vaccine 17d or 17dd-associated serious adverse events in pharmacovigilance data bases: Systematic review

Current Drug Safety

Volumn 6, Issue 3, 2011, Pages 145-154

  Thomas, Roger E ^a   Lorenzetti, Diane L ^b   Spragins, Wendy ^b   Jackson, Dave ^b   Williamson, Tyler ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Departments of Community Health Sciences and Family Medicine   (Canada)

Author keywords

Pharmacovigilance; Risk of bias; Serious adverse effects; Systematic review; Yellow fever; Yellow fever 17D and 17DD vaccine

Indexed keywords

YELLOW FEVER VACCINE;

ABSCESS; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLACTIC SHOCK; ARTHRALGIA; ARTICLE; AUSTRALIA; BRAZIL; CONVULSION; DATA BASE; DIARRHEA; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; FEVER; FLU LIKE SYNDROME; GUILLAIN BARRE SYNDROME; HALLUCINATION; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INJECTION SITE ULCER; JAUNDICE; LYMPHADENOPATHY; MENINGISM; MENTAL HEALTH; MYALGIA; MYELITIS; NEUROLOGIC DISEASE; PARALYSIS; PARESTHESIA; PAROTITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RHABDOMYOLYSIS; SEIZURE; SIDE EFFECT; SWELLING; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNITED KINGDOM; URTICARIA; VACCINATION; VERTIGO; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HUMANS; NEUROTOXICITY SYNDROMES; PHARMACOVIGILANCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 80054120802     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611797579258     Document Type: Article

References (35)

1. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 2007; 25(15): 2758-65.
2. WHO Emerging and Other Communicable Diseases. District guidelines for yellow fever surveillance. Geneva: World Health Organization; 1998. Report No.:WHO/EPI/GEN/98.09.
3. WHO GAR Global Alert and Response. EPR strategy and activities - yellow fever epidemics risk assessment. World Health Organization 2010 [cited 2010 May 10]; Available from: URL: http://www.who.int/csr/disease/yellowfev/strategy_activities/en/#assessment
4. Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA 2008; 300(8): 960-2.
5. Ellis BR, Barrett AD. The enigma of yellow fever in East Africa. Rev Med Virol 2008; 18(5): 331-46.
6. Meeting of Global Advisory Committee on Vaccine Safety, 18-19 June 2008. Wkly Epidemiol Rec 2008; 83(32): 287-92.
7. Bae HG, Domingo C, Tenorio A, et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008; 197(11): 1577-84.
8. Guimard T, Minjolle S, Polard E, et al. Incidence of yellow Fever vaccine-associated neurotropic disease. Am J Trop Med Hyg 2009; 81(6): 1141-3.
9. Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999; 103(4): 698-701.
10. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004; 22(17-18): 2103-5.
11. Levy S, Centers for Disease Control and Prevention (CDC). Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002; 51(44): 989-93.
12. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26(48): 6077-82.
13. McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007; 25(10): 1727-34.
14. Monath T, Cetron M, Teuwen D. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, Eds. Vaccines. 5th ed. Philadelphia: Saunders/Elsevier 2008: pp. 959-1056.
15. Struchiner CJ, Luz PM, Dourado I, et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 2004; 132(5): 939-46.
16. Vellozzi C, Mitchell T, Miller E, Casey CG, Eidex RB, Hayes EB. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. Am J Trop Med Hyg 2006; 75(2): 333-6.
17. Whittembury A, Ramirez G, Hernandez H, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009; 27(43): 5974-81.
18. Martins MA, Silva ML, Marciano AP, et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol 2007; 148(1): 90-100.
19. Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 2004; 28(2): 244-8.
20. Lawrence G, Menzies R, Burgess M, et al. Surveillance of adverse events following immunisation: Australia, 2000-2002. Commun Dis Intell 2003; 27(3): 307-23.
21. Martins RDM, Maia MDLD, Santos EMD, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Proc Vaccinol 2010; 2(2): 178-83.
22. Schumacher Z, Bourquin C, Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland-1991-2001. Vaccine 2010; 28(24): 4059-64.
23. Monath TP, Cetron MS, McCarthy K, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccine 2005; 1(5): 207-14.
24. Martin M, Weld LH, Tsai TF, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7(6): 945-51.
25. Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005; 23(25): 3256-63.
26. Bonhoeffer J, Kohl K, Chen R, et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002; 21(3-4): 298-302.
27. Bonhoeffer J, Heininger U, Kohl K, et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 2004; 22(5-6): 547-50.
28. Bonhoeffer J, Bentsi-Enchill A, Chen RT, et al. Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine 2009; 27(16): 2289-97.
29. Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine 2010; 28(28): 4487-98.
30. Souayah N, Nasar A, Suri MFK, Qureshi AI. Guillain-Barre syndrome after vaccination in United States. A report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 2007; 25(29): 5253-5.
31. Review of adverse events reported following use of yellow fever vaccine--Canada, 1987-2000. Can Commun Dis Rep 2002; 28(2): 9-15.
32. From the Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002. JAMA 2002; 288(20): 2533-5.
33. Bentancourt S, Valsecia M, Perez A, Bergman M, Bignone K. Adverse events supposedly attributable to vaccination of yellow fever. Drug Saf 2008; 31(10): 942.
34. Fernandes GC, Camacho LA, Sa Carvalho M. Surveillance system of vaccine adverse events and local data analysis--the experience in a middle-sized city in Brazil, 1999-2001. Vaccine 2005; 23(17-18): 2349-53.
35. Fernandes GC, Camacho LA, Sa Carvalho M, Batista M, de Almeida SM. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Vaccine 2007; 25(16): 3124-8.